CD133联合外周循环肿瘤细胞在结直肠癌预后评估中的应用研究

Combined use of CD133 and circulating tumor cells CTC for evaluating prognosis of colorectal cancer

目的探讨CD133联合外周循环肿瘤细胞(circulating tumor cell,CTC)在结直肠癌预后评估应用的可行性。方法随访福建省立医院124例结直肠癌病例,检测癌组织中CD133表达及CTC;分为4个组:CD133^-低水平量CTC(L-CTC)组(59例)、CD133^-高水平量CTC(H-CTC)组(21例)、CD133^+L-CTC组(35例)、CD133^+H-CTC组(9例),比较4组3年生存曲线。结果 CD133^-LCTC组生存时间为(1 002.8±39.1)d,与CD133^+L-CTC组的(980.5±38.8)d之间差异无统计学意义(P>0.05);但明显高于CD133^-H-CTC组的(782.5±75.8)d及CD133^+H-CTC组的(368.6±31.0)d,差异均有统计学意义(均P<0.05);CD133^+L-CTC组生存时间明显高于CD133^-H-CTC组及CD133^+H-CTC组,差异均有统计学意义(均P<0.05);CD133^-H-CTC组生存时间明显高于CD133^+H-CTC组,两组之间差异有统计学意义(P<0.05)。结论 CD133联合CTC可用于结直肠癌术后3年生存时间评估。

Objective To explore the feasibility of combined use of CD133 and circulating tumor cells（CTC）for evaluating the prognosis of colorectal cancer.Methods 124 cases of colorectal cancer in our hospital were followed up,and the expression of CD133 and CTC in cancer tissues were detected.The patients were divided into four groups：CD133^-L-CTC（n=59）,CD133^-H-CTC（n=21）,CD133＋~L-CTC（n=35）and CD133＋~H-CTC（n=9）.The 3^-year survival curves were compared among the four groups.Results The average survival time in CD133^-L-CTC group was（1 002.8±39.1）days,which was not significantly different from that in CD133＋~L-CTC group[（980.5±38.8）days],but significantly longer than that in CD133^-H-CTC group[（782.5±75.8）days]and CD133＋~H-CTC group[（368.6±31.0）days]（P〈0.05）The average survival time in CD133＋~L-CTC group was significantly longer than that in CD133^-H-CTC group and CD133＋~H-CTC group.P〈0.05,and that in CD133^-H-CTC group was significantly longer than that in CD133＋~H-CTC group,P〈0.05.Conclusions CD133 combined with CTC can be used to evaluate the three^-year survival time of colorectal cancer.